TR200000562T2 - Amlodifin ve bir statin bileşiği içeren bileşim terapisi - Google Patents

Amlodifin ve bir statin bileşiği içeren bileşim terapisi

Info

Publication number
TR200000562T2
TR200000562T2 TR2000/00562T TR200000562T TR200000562T2 TR 200000562 T2 TR200000562 T2 TR 200000562T2 TR 2000/00562 T TR2000/00562 T TR 2000/00562T TR 200000562 T TR200000562 T TR 200000562T TR 200000562 T2 TR200000562 T2 TR 200000562T2
Authority
TR
Turkey
Prior art keywords
statin compound
therapy containing
containing amlodipine
composition therapy
amlodipine
Prior art date
Application number
TR2000/00562T
Other languages
English (en)
Inventor
Buch Jan
Andrew Donald Scott Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000562(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200000562T2 publication Critical patent/TR200000562T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Bu bulus, amlodifin veya bunun farmakolojik olarak uygun asit ekleme tuzlari ve statinler veya bunlarin farmakolojik olarak uygun tuzlarindan olusan farmakolojik bilesimlerle, bu gibi bilesimleri içeren donanimlarla, anjin pektoris, aterosklerosis, hipertansiyon ve hiperlipidemia'nin birlikte bulundugu durumlardan rahatsizlik çeken öznelerin tedavisinde ve insanlar da dahil olmak üzere kalp hastaliklariyla ilgili risk tasiyan öznelerin tedavisinde bu gibi bilesimleri kullanma metodlariyla ilgilidir.
TR2000/00562T 1997-08-29 1998-08-10 Amlodifin ve bir statin bileşiği içeren bileşim terapisi TR200000562T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
TR200000562T2 true TR200000562T2 (tr) 2000-08-21

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00562T TR200000562T2 (tr) 1997-08-29 1998-08-10 Amlodifin ve bir statin bileşiği içeren bileşim terapisi

Country Status (36)

Country Link
US (1) US20020025981A1 (tr)
EP (1) EP1003507A1 (tr)
JP (1) JP2001514224A (tr)
KR (1) KR20010022385A (tr)
CN (1) CN1117566C (tr)
AP (1) AP1207A (tr)
AR (1) AR017514A1 (tr)
AU (1) AU744982B2 (tr)
BG (1) BG104076A (tr)
BR (1) BR9811558A (tr)
CA (1) CA2296726C (tr)
CO (1) CO4970726A1 (tr)
DZ (1) DZ2600A1 (tr)
EA (1) EA002705B1 (tr)
GT (1) GT199800134A (tr)
HN (1) HN1998000124A (tr)
HR (1) HRP980475A2 (tr)
HU (1) HUP0003103A3 (tr)
ID (1) ID24275A (tr)
IL (2) IL133957A0 (tr)
IS (1) IS5345A (tr)
MA (1) MA26539A1 (tr)
NO (1) NO20000999D0 (tr)
NZ (1) NZ502283A (tr)
OA (1) OA11289A (tr)
PA (1) PA8457201A1 (tr)
PE (1) PE106999A1 (tr)
PL (1) PL339088A1 (tr)
SA (1) SA98190432A (tr)
SK (1) SK1392000A3 (tr)
TN (1) TNSN98158A1 (tr)
TR (1) TR200000562T2 (tr)
UY (1) UY25159A1 (tr)
WO (1) WO1999011263A1 (tr)
YU (1) YU2700A (tr)
ZA (1) ZA987843B (tr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506822A (ja) 1992-05-19 1995-07-27 ノボゲン　リサーチ　ピーティーワイ　リミッテッド フィト−エストロゲン，類似体またはその代謝産物を含有する健康補助剤
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
WO2007111027A1 (ja) * 2006-03-29 2007-10-04 Kowa Co., Ltd. トリグリセリド低下剤及び高インスリン血症改善剤
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR101207618B1 (ko) * 2008-02-22 2012-12-04 한올바이오파마주식회사 심혈관계 질환 치료용 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2010008203A2 (ko) * 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
EP2629797B1 (en) 2010-10-19 2018-05-23 The Regents of the University of Colorado, A Body Corporate Peptides for modulating t-cell activity and uses thereof
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
WO2019094581A1 (en) * 2017-11-10 2019-05-16 Op-T Llc Methods for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
WO2021108343A1 (en) * 2019-11-25 2021-06-03 Fordoz Pharma C0Rp. Formulations comprising lipid-lowering and blood pressure-lowering drugs
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (tr) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
UY25159A1 (es) 2000-12-29
ID24275A (id) 2000-07-13
IL133957A0 (en) 2001-04-30
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
NO20000999L (no) 2000-02-28
CN1117566C (zh) 2003-08-13
HRP980475A2 (en) 1999-06-30
HUP0003103A2 (hu) 2001-01-29
AR017514A1 (es) 2001-09-12
HK1029530A1 (en) 2001-04-06
JP2001514224A (ja) 2001-09-11
IS5345A (is) 2000-01-14
SA98190432A (ar) 2005-12-03
AP1207A (en) 2003-09-20
AP9801333A0 (en) 1998-09-30
PL339088A1 (en) 2000-12-04
HUP0003103A3 (en) 2002-03-28
EA200000013A1 (ru) 2000-08-28
US20020025981A1 (en) 2002-02-28
ZA987843B (en) 2000-02-28
CO4970726A1 (es) 2000-11-07
DZ2600A1 (fr) 2003-03-01
BR9811558A (pt) 2000-08-22
NZ502283A (en) 2002-05-31
EP1003507A1 (en) 2000-05-31
CA2296726A1 (en) 1999-03-11
CN1268054A (zh) 2000-09-27
KR20010022385A (ko) 2001-03-15
PA8457201A1 (es) 2000-05-24
AU8458598A (en) 1999-03-22
YU2700A (sh) 2002-06-19
IL133957A (en) 2006-06-11
CA2296726C (en) 2004-06-29
HN1998000124A (es) 1999-02-09
GT199800134A (es) 2000-02-08
WO1999011263A1 (en) 1999-03-11
BG104076A (en) 2000-09-29
MA26539A1 (fr) 2004-12-20
NO20000999D0 (no) 2000-02-28
EA002705B1 (ru) 2002-08-29
AU744982B2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
TR200000561T2 (tr) Amlodipin ve atorvastatin içeren tedavisel bileşikler.
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
TR200000563T2 (tr) Atorvastatin ve bir antihipertensif vasıta içeren bileşim terapisi.
YU2700A (sh) Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja
BR9815039A (pt) Inibição da oxidação de lipoproteìna
ATE288893T1 (de) Polymorphe form von atorvastatin-calcium
DE69822839D1 (de) Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
EE9600072A (et) Uudne ravimsegu, mis sisaldab ACE inhibiitorit ramipriili ja dihüdropüridiinühendit
TR199801195T2 (tr) Tedavide yararli kinolin ve kinozilin bilesikleri.
TR200200518T2 (tr) Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar
BG106128A (bg) Обща сол на aмлодипин и аторвастатин
DE69614149D1 (de) Chinolinderivate als antimalariamittel
TR200001869T2 (tr) Terapetik Maddeler
TR200103391T2 (tr) Amlodipin ve atorvastatinin ön ilaçları.
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
DE69710305D1 (de) Derivate von 4-Vinyl-4'-alpha-hydroxyethyl-biphenyl
ECSP982647A (es) Terapia de combinacion
ECSP982645A (es) Terapia de combinacion
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler
ECSP982646A (es) Combinaciones terapeuticas
BR9814114A (pt) Uso de quinapril para o tratamento de isquemia miocárdica e angina